Plus, news about Merck, Beijing Jacobio, Immunai, BridGene Biosciences and Spyre Therapeutics:
🇨🇳 Dianthus Therapeutics licenses autoimmune asset from China: The biotech will pay $30 million upfront to Nanjing Leads Biolabs ...
↧